About BerGenBio
OSE: BGBIO
BerGenBio is a clinical-stage biopharmaceutical company developing innovative drugs for aggressive diseases, including cancer and severe respiratory infections
![Happy couple](/_next/image?url=%2F_next%2Fstatic%2Fmedia%2Fhappy.2cebb730.jpg&w=1920&q=85)
AXL: a promising target to treat life-threatening diseases
BerGenBio is developing two highly selective and potent AXL inhibitors bemcentinib and tilvestamab
Key Roles of AXL
- Invasion/Migration
- Drug resistance
- Proliferation
- Survival
- Immune suppression
- Viral entry cofactor
- Immune supression
- Extracellular matric production
- Migration
- Basal cell proliferation
- Reduced cytokine signalling
BGB’s AXL Inhibiters
- Orally bioavailable small molecule TKI
- Potent, selective AXL inhibition
- Once-a-day administration
- Favorable safety profile
- Single agent and combination activity
- Anti-AXL fully humanized monoclonal antibody
- Highly selective to human AXL
- Stable formulation, scalable manufacturing process
![cancer cell](/_next/image?url=%2F_next%2Fstatic%2Fmedia%2FCancerCell.27884063.png&w=1920&q=85)
![Happy woman making a deal](/_next/image?url=%2F_next%2Fstatic%2Fmedia%2Fhandshake.3f3f5e19.png&w=1200&q=85)
Business model: R&D excellence and strategic partnerships
BerGenBio is leveraging its solid leadership position in understanding the role of AXL in diseases of high unmet need to develop a diversified pipeline of selective AXL inhibitors.
Partnerships based on BerGenBio’s pioneering R&D are being employed strategically with:
ADC Therapeutics SA, a Swiss biotechnology firm, with whom BerGenBio has entered a licensing agreement to develop an AXL-ADC.
An extensive network of leading clinical sites and key opinion leaders with whom BerGenBio works to ideally position its investigational product candidates.